Table 1- Omalizumab dosing
|
Pre-tx serum IgE (IU/mL) |
Body weight (kg) 30-60
|
Body weight (kg)>60-70 |
Body weight (kg)>70-90 |
Body weight (kg)>90-150 |
|
30-100 |
150mg- Q4 weeks |
150mg Q4 weeks |
150mg Q4 weeks |
300mg Q4 weeks |
|
>100-200 |
300mg Q4 weeks |
300mg Q4 weeks |
300mg Q4 weeks |
225mg Q2 weeks |
|
>200-300 |
300mg Q4 weeks |
225mg Q2 weeks |
225mg Q2 weeks |
300mg Q2 weeks |
|
>300-400 |
225mg Q2 weeks |
225mg Q2 weeks |
300mg Q2 weeks |
Do not dose |
|
>400-500 |
300mg Q2 weeks |
300mg Q2 weeks |
375mg Q2 weeks |
Do not dose |
|
>500-600 |
300mg Q2 weeks |
375mg Q2 weeks |
Do not dose |
Do not dose |
|
>600-700 |
375mg Q2 weeks |
Do not dose |
Do not dose |
Do not dose |
Table 2 Eight trials reviewed done by the Cochran Group with a total of 2037 mild to severe allergic asthmatic participants with high levels of IgE.
|
|
Number of Trials |
odds ratio with confidence interval of 95% |
|
Increases in the number of participants using omalizumab who were able to reduce steroids by over 50%: |
4 of 8 |
2.5 |
|
Users of omalizumab completely withdraw their daily steroid intake |
4 of 8 |
2.5 |
|
Less likely to suffer an asthma exacerbation with treatment with omalizumab as an adjunct to steroids |
4 of 8 |
0.49 |
|
Less likely to suffer an asthma exacerbation with treatment with omalizumab as a steroid tapering agent |
4o 8 |
0.47 |